<DOC>
	<DOCNO>NCT01703208</DOCNO>
	<brief_summary>The purpose study evaluate cardiovascular ( CV ) safety profile omarigliptin participant type 2 diabetes mellitus ( T2DM ) . The primary hypothesis treatment omarigliptin 25 mg weekly non-inferior treatment placebo active comparators across omarigliptin program regard risk develop confirmed event primary CV composite endpoint .</brief_summary>
	<brief_title>A Study Assess Cardiovascular Outcomes Following Treatment With Omarigliptin ( MK-3102 ) Participants With Type 2 Diabetes Mellitus ( MK-3102-018 )</brief_title>
	<detailed_description>The trial amend extend length trial order meet FDA requirement post-approval assessment cardiovascular ( CV ) safety . The trial contain 2 time interval : Period 1 Period 2 . Period 1 refers time interval recent protocol amendment Period 2 , time interval protocol amendment end study . Participants Period 1 re-consented continue Period 2 . If require , additional participant enrol Period 2 . Stage 1 refers prefiling United States Food Drug Administration ( US FDA ) requirement rule 80 % increase CV risk . Stage 2 refers US FDA post-marketing requirement rule 30 % increase CV risk . The Stage 1 assessment CV risk occur Period 1 base meta-analysis major adverse CV event ( MACE ) unstable angina across omarigliptin Phase 2/Phase 3 program . The Stage 2 assessment base MACE P018 alone include CV event Period 1 Period 2 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus Is one follow diabetes treatment regimen stable least 12 week ( except pioglitazone least 16 week ) within associate A1C range treatment regimen : 1 . A1C &gt; = 6.5 % &lt; = 10.0 % ( &gt; =48 mmol/mol &lt; =86 mmol/mol ) : ( ) diet exercise alone ( antihyperglycemic agent [ AHA ] &gt; = 12 week ) OR ( b ) monotherapy metformin ( MF ) , pioglitazone ( PIO ) alphaglucosidase inhibitor ( AGI ) sodiumglucose cotransporter inhibitor ( SGLT2i ) OR ( c ) dual combination therapy MF , PIO , AGI SGLT2i OR 2 . A1C &gt; = 7.0 % &lt; =10.0 % ( &gt; =53 mmol/mol &lt; =86 mmol/mol ) ( ) monotherapy sulfonylurea meglitinide OR ( b ) dual combination therapy sulfonylurea meglitinide MF , PIO , AGI , SGLT2i OR 3 . A1C &gt; =7.0 % &lt; =10.0 % ( &gt; =53 mmol/mol &lt; =86 mmol/mol ) one follow insulin regimen ( without metformin ) : ( ) basal insulin ( e.g . ; insulin glargine , insulin detemir , NPH insulin , degludec ) OR ( b ) prandial insulin ( e.g . regular , aspart , lispro , glulisine ) OR ( c ) basal/prandial insulin regimen consist multiple dose insulin injection basal prandial insulin use premixed insulin ( e.g. , Novolog 70/30速 , Novolin 70/30速 , Humalog 75/25速 , Humulin 70/30速 Preexisting vascular disease ( coronary artery disease , ischemic cerebrovascular disease , atherosclerotic peripheral artery disease ) ( 1 ) Male ; ( 2 ) female reproductive potential ; ( 3 ) female reproductive potential agrees remain abstinent use alone conjunction partner 2 method contraception prevent pregnancy study 21 day last dose study drug . History type 1 diabetes mellitus history ketoacidosis Treated rosiglitazone , dipeptidyl peptidaseIV ( DPP4 ) inhibitor , glucagonlike peptide1 ( GLP1 ) receptor agonist within 12 week prior study participation previously treat omarigliptin On weight loss program maintenance phase weight loss medication past 6 month undergone bariatric surgery within 12 month prior study participation Medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Human immunodeficiency virus ( HIV ) assess medical history New worsen coronary heart disease , congestive heart failure , myocardial infarction , unstable angina , coronary artery intervention , stroke , transient ischemic neurological disorder within past 3 month History malignancy &lt; =5 year prior study participation , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer Clinically important hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Pregnant breast feeding , expect conceive donate egg trial , include 21 day follow last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>